Bioprocessing and the Production of Antiviral Biologics Helps in Prevention and Treatment of Disease

Neil Rown^*
*Correspondence: Neil Rown, Department of Bioprocess Engineering, Atlantic Technological University, Sligo, Ireland, Email:

Keywords

Bioprocessing • Antiviral • Revolutionized • Immune

Introduction

Antiviral biologics have emerged as a powerful tool in the fight against viral diseases. Unlike traditional small-molecule drugs, which often act on multiple targets and can lead to off-target effects, antiviral biologics are designed to specifically target viral components or modulate the host immune response. This specificity allows for highly effective and precise therapeutic interventions, minimizing adverse effects on healthy cells and tissues [1].

Bioprocessing plays a critical role in the production of antiviral biologics, ensuring their safety, efficacy, and scalability. It encompasses a series of interconnected steps, including cell culture, downstream processing, and formulation, each of which is essential to the production of high-quality biologics. Cell culture is the initial step in the production of antiviral biologics. It involves growing cells in a controlled environment, typically using bioreactors, to produce the desired therapeutic protein or antibody. Bioprocessing techniques optimize cell growth conditions, such as nutrient supply, oxygenation, and pH control, to maximize productivity and yield. Additionally, genetic engineering approaches can be employed to enhance cell lines for increased protein expression or to introduce specific modifications that improve biologic properties. Following cell culture, downstream processing involves the isolation, purification, and characterization of the desired biologic product. This step is crucial for removing impurities and contaminants, ensuring the final product's safety and efficacy. Bioprocessing techniques such as filtration, chromatography, and viral inactivation steps are employed to achieve high product purity and yield. These techniques have been refined over the years, allowing for more efficient and cost-effective purification processes [2].

Formulation refers to the final step of product preparation, where the purified biologic is formulated into a stable and biocompatible dosage form. Bioprocessing techniques are utilized to optimize the formulation, ensuring stability and proper delivery of the biologic to the patient. This step also considers factors like storage conditions and shelf life to maintain product integrity throughout its lifecycle. Antiviral biologics offer several advantages over traditional small-molecule drugs in the prevention and treatment of viral diseases [3].

Literature Review

Antiviral biologics can be designed to specifically target viral components, such as viral proteins or receptors, increasing their efficacy and minimizing off-target effects. By selectively neutralizing or blocking viral entry, replication, or other essential processes, antiviral biologics disrupt the viral life cycle and reduce viral load more effectively. Some antiviral biologics, such as monoclonal antibodies, can modulate the host immune response to enhance viral clearance. These antibodies can bind to viral particles or infected cells, facilitating their recognition and elimination by immune cells. By boosting the immune system's natural defense mechanisms, antiviral biologics provide an additional layer of protection against viral infections. Many antiviral biologics confer longlasting protection, as they stimulate the immune system to produce memory cells that can recognize and respond to future viral encounters. This immune memory can provide durable immunity, reducing the likelihood of reinfection or disease recurrence. Bioprocessing plays a crucial role in the production of antiviral biologics, enabling their widespread availability and improving disease prevention and treatment. By optimizing cell culture, downstream processing, and formulation techniques, bioprocessing ensures the efficient and cost-effective production of high-quality biologics. Antiviral biologics offer distinct advantages over traditional drugs, including specificity, immune modulation, and long-lasting protection. The continued advancement of bioprocessing techniques holds the promise of further enhancing the development and production of antiviral biologics, leading to improved clinical outcomes and the ability to combat a wider range of viral diseases [4].

Discussion

One of the key advantages of bioprocessing in the production of antiviral biologics is the ability to generate large quantities of these therapeutic agents. Viral diseases often require a rapid response, especially in the case of pandemics or outbreaks. Bioprocessing techniques, such as cell culture and fermentation, enable the production of antiviral biologics in large-scale bioreactors, allowing for the rapid and efficient generation of therapeutic doses to meet the demand. Monoclonal antibodies are a prominent example of antiviral biologics produced through bioprocessing. These antibodies are engineered to specifically target and neutralize viral pathogens, preventing their entry into host cells or blocking essential viral proteins. Bioprocessing techniques, such as hybridoma technology and recombinant DNA technology, are employed to produce these antibodies in large quantities. These techniques involve the culture of antibodyproducing cells or the expression of antibody genes in host cells, respectively. Through bioprocessing, monoclonal antibodies can be manufactured on an industrial scale, ensuring their availability for widespread use in the prevention and treatment of viral diseases [5,6].

Conclusion

Another vital area where bioprocessing plays a significant role is the production of antiviral vaccines. Vaccines are a cornerstone of disease prevention, and the development of effective antiviral vaccines is crucial in combating viral outbreaks. Bioprocessing techniques are used to produce viral vaccines by cultivating the viral antigen or genetic material in host cells, such as bacteria, yeast, or mammalian cells. This allows for the large-scale production of viral proteins or the generation of viral particles for vaccine formulation. Bioprocessing enables the production of vaccines in a controlled environment, ensuring consistency, purity, and safety in the final product. The production of antiviral biologics through bioprocessing has a profound impact on disease prevention and treatment. Firstly, the availability of large quantities of antiviral biologics allows for effective prophylaxis, especially in high-risk populations or areas experiencing viral outbreaks. Prophylactic administration of antiviral biologics, such as monoclonal antibodies or vaccines, can help prevent viral infections or reduce the severity of symptoms in individuals who have been exposed to the virus. These not only protects individuals but also contributes to public health by limiting the spread of infectious diseases. Antiviral biologics produced through bioprocessing have revolutionized the treatment of viral diseases. Traditional antiviral drugs often target viral enzymes or processes, but they can be limited in efficacy or prone to the development of drug resistance. Antiviral biologics, on the other hand, offer a more targeted approach by directly neutralizing the virus or modulating the immune response.

Acknowledgement

None.

Conflict of Interest

There is no conflict of interest by author.

References

1. Pollard, Andrew J. and Else M. Bijker. "A guide to vaccinology: From basic principles to new developments." Nat Rev Immunol 21 (2021): 83-100.

Google Scholar, Crossref, Indexed at

2. Nosaki, Shohei, Ken Hoshikawa, Hiroshi Ezura and Kenji Miura. "Transient protein expression systems in plants and their applications." Plant Biotechnol 38 (2021): 297-304.

Google Scholar, Crossref, Indexed at

3. Ojha, Rupal and Vijay Kumar Prajapati. "Cognizance of posttranslational modifications in vaccines: A way to enhanced immunogenicity." J Cell Physiol 236 (2021): 8020-8034.

Google Scholar, Crossref, Indexed at

4. Garvey, Mary. "Non-Mammalian eukaryotic expression systems yeast and fungi in the production of biologics." J Fungi 8 (2022): 1179.

Google Scholar, Crossref, Indexed at

5. Vieira Gomes, Antonio Milton, Talita Souza Carmo, Lucas Silva Carvalho and Frederico Mendonça Bahia, et al. "Comparison of yeasts as hosts for recombinant protein production." Microorganisms 6 (2018): 38.

Google Scholar, Crossref, Indexed at

6. Legastelois, Isabelle, Sophie Buffin, Isabelle Peubez and Charlotte Mignon, et al. "Non-conventional expression systems for the production of vaccine proteins and immunotherapeutic molecules." Hum Vaccines Immunother 13 (2017): 947-961.

Google Scholar, Crossref, Indexed at